Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Peripheral arterial disease

Peripheral arterial disease

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Peripheral arterial disease

109 trials tracked for Peripheral arterial disease: 17 in phase 3 or 4 and 6 with published results. The most-cited published study has 215 citations.

109Trials tracked
17Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 9 Phase 3 8 Phase 2 11 Phase 1 2 Other / NA 79
  1. Phase 3 Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis Completed · 215 cited
  2. Phase 3 A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes Completed · 134 cited
  3. Phase 4 A Randomized Clinical Trial Evaluating Negative Pressure Therapy to Decrease Vascular Groin Incision Complications Completed · 97 cited
  4. Phase 4 Liraglutide and Peripheral Artery Disease Completed · 56 cited
  5. Phase 4 Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies Completed · 23 cited
  6. Phase 4 Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus Completed · 19 cited
Show 44 more trials
  1. Phase 4 The Jetstream G3™ Calcium Study Completed
  2. Phase 4 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed
  3. Phase 4 DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases Completed
  4. Phase 4 Evaluation of Cilostazol in Combination With L-Carnitine Completed
  5. Phase 4 Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease Completed
  6. Phase 3 Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities Completed
  7. Phase 3 Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE Completed
  8. Phase 3 Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease Completed
  9. Phase 3 Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++) Completed
  10. Phase 3 Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Completed
  11. Phase 3 Strength Training in Walking Tolerance in Intermittent Claudication Patients Completed
  12. Phase 2 Remote Ischemic Preconditioning Prior to Vascular Surgery Completed
  13. Phase 2 OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO Completed
  14. Phase 2 Creatine Use and Muscle Stretching in Peripheral Artery Disease Completed
  15. Phase 2 Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial Completed
  16. Phase 2 Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD Completed
  17. Phase 2 Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease Completed
  18. Phase 2 A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia Completed
  19. Phase 2 Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC Completed
  20. Phase 2 Polestriding Versus Walking for Subjects With Poor Leg Circulation Completed
  21. Phase 2 Edoxaban in Peripheral Arterial Disease Completed
  22. Phase 2 Nitrites, Exercise, and Peripheral Arterial Disease Completed
  23. Phase 1 N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes Completed
  24. Phase 1 A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease Completed
  25. N/A EverFlex Post Approval Study Completed
  26. N/A Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2) Completed
  27. N/A Collaborative-care Rehabilitation After Dysvascular Amputation Completed
  28. N/A Exercise Rehabilitation in Veterans With PAD Completed
  29. N/A Disrupt PAD+ Study With the Shockwave Medical M5+ Peripheral IVL System Completed
  30. N/A DURABILITY™ Iliac Study Completed
  31. N/A Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics. Completed
  32. N/A VISIBILITY™ Iliac Study Completed
  33. N/A Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries Completed
  34. N/A A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers. Completed
  35. N/A A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL) Completed
  36. N/A Electrical Stimulation to Accelerate Wound Healing Completed
  37. N/A ILLUMENATE EU Randomized Clinical Trial Completed
  38. N/A Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME) Completed
  39. N/A Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease Completed
  40. N/A Intermittent Pneumatic Compression to Improve Revascularization Outcome Completed
  41. N/A Heat Therapy to Reduce Pain and Improve Walking Tolerance Completed
  42. N/A Safety and Performance Study of the Shockwave Lithoplasty System Completed
  43. N/A Chronic Total Occlusion Crossing With the Wildcat Catheter Completed
  44. N/A The DETOUR 2 Clinical Trial Completed

Showing the 50 most-cited and recently-updated of 109 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Peripheral arterial disease: what the trials found

Prevena Care is a newly established intervention for peripheral arterial disease 1. Pharmacological management shows that Semaglutide significantly improves functional outcomes, including an increase in maximum walking distance on constant load treadmill tests and improved VascuQoL-6 scores 14. Liraglutide was associated with a significant decrease in peripheral transcutaneous oxygen pressure (p<0.001), though it did not show statistically significant changes in HbA1c or glucose levels 5.

Interventional procedures demonstrate varying efficacy: the Jetstream Atherectomy System significantly increased luminal area 8, and specific plaque excision systems (SilverHawk, TurboHawk) showed a 92% successful revascularization rate with a 93.1% major adverse event-free rate at 30 days 17. Regarding pharmacotherapy for secondary prevention and management, Vorapaxar demonstrated a lower rate of major cardiovascular events (CV death, MI, stroke) over 3 years compared to the control group (p<0.001) while also showing significantly lower rates of severe bleeding 18. Ezetimibe was shown to reduce total cholesterol by 30 mg/dl at month 12 9.

Other findings include that walking training significantly increased total walking distance 20. Regarding antiplatelet therapy, Rivaroxaban 2.5 mg showed significant effects on thrombin generation (p<0.001) but no significant impact on platelet-mediated global thrombogenicity or VerifyNow PRU 6. Clopidogrel did not show a statistically significant difference in the number of participants experiencing first occurrences of bleeding 15. Cilostazol showed a statistically significant increase in peak walking time at 180 days (p=0.048), but no significant change was observed at 90 days 10.

recent

• The LifeStream Peripheral Stent Graft System reported primary patency rates of 0, 1, 4, 4, 4, and 7 at intervals ranging from 1 to 60 months post-procedure 4. • Creatine monohydrate did not show statistically significant improvements in walking distance or oxygenation per second 21.

For the clinician treating this condition

  • Semaglutide is associated with improved walking distance and quality of life scores in patients with peripheral arterial disease 14.
  • The Jetstream Atherectomy System significantly increases luminal area, and specific plaque excision systems demonstrate high success rates for revascularization [8, 17].
  • Vorapaxar showed a significant reduction in major cardiovascular events (CV death, MI, stroke) over a 3-year period compared to standard treatment 18.
  • Liraglutide significantly improves peripheral transcutaneous oxygen pressure 5.

AI synthesis of 13 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
IVUS-guided PVI reduces amputation, TLR, restenosis, and all-cause mortality in peripheral arterial disease
Radiology & Imaging Meta-analysis
IVUS-guided PVI reduces amputation, TLR, restenosis, and all-cause mortality in peripheral arterial disease Ultrasound guidance may lower amputation risk for peripheral artery disease
This meta-analysis of 1,110,593 patients undergoing peripheral vascular interventions for peripheral arterial disease found that IVUS-guided…
Using ultrasound during procedures for blocked leg arteries could reduce risks like amputation and death compared to standard imaging alone.
Aug 5, 2026
Psoas Major Muscle Area as a Prognostic Marker in Peripheral Arterial Disease
Orthopedics & Sports Medicine Meta-analysis
Psoas Major Muscle Area as a Prognostic Marker in Peripheral Arterial Disease Muscle size in the lower back predicts survival for PAD patients
Reduced psoas muscle size correlates with higher one-year mortality in patients undergoing revascularization for peripheral arterial disease…
A smaller psoas muscle area may signal a higher risk of death for people undergoing surgery for peripheral arterial disease.
Frontiers Jul 24, 2026
Patients with cardiovascular diseases show measurable prevalence of active cancer across multiple conditions
Cardiology Sys. Review
Patients with cardiovascular diseases show measurable prevalence of active cancer across multiple conditions Heart disease patients show measurable risk of developing various cancers
This systematic review and meta-analysis analyzed 4,759,695 patients to determine the prevalence of active cancer in individuals with variou…
New data shows that people with heart conditions like stroke or heart failure have a measurable rate of active cancer cases.
medRxiv Jul 9, 2026